Afatinib in advanced pretreated non-small-cell lung cancer— a Canadian experience

BACKGROUND: Afatinib, an irreversible epidermal growth factor receptor tyrosine kinase inhibitor (egfr tki), is approved for first-line therapy in advanced EGFR mutation–positive non-small-cell lung cancer (nsclc) and has previously demonstrated activity after failure of chemotherapy and reversible...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Curr Oncol
Prif Awduron: Ezeife, D.A., Melosky, B., Tudor, R., Lin, S., Lau, A., Panzarella, T., Leighl, N.B.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Multimed Inc. 2018
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6209553/
https://ncbi.nlm.nih.gov/pubmed/30464688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.3914
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg